- Home
- PRPH vs MRKR Comparison
PRPH vs MRKR Comparison
Compare PRPH & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPH
- MRKR
- Stock Information
- Founded
- PRPH 1989
- MRKR N/A
- Country
- PRPH United States
- MRKR United States
- Employees
- PRPH N/A
- MRKR N/A
- Industry
- PRPH Biotechnology: Pharmaceutical Preparations
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- PRPH Health Care
- MRKR Health Care
- Exchange
- PRPH Nasdaq
- MRKR Nasdaq
- Market Cap
- PRPH 17.7M
- MRKR 17.7M
- IPO Year
- PRPH 1997
- MRKR N/A
- Fundamental
- Price
- PRPH $0.28
- MRKR $1.19
- Analyst Decision
- PRPH
- MRKR Strong Buy
- Analyst Count
- PRPH 0
- MRKR 3
- Target Price
- PRPH N/A
- MRKR $13.17
- AVG Volume (30 Days)
- PRPH 1.1M
- MRKR 3.5M
- Earning Date
- PRPH 08-13-2025
- MRKR 08-18-2025
- Dividend Yield
- PRPH N/A
- MRKR N/A
- EPS Growth
- PRPH N/A
- MRKR N/A
- EPS
- PRPH N/A
- MRKR N/A
- Revenue
- PRPH $5,845,000.00
- MRKR $5,696,123.00
- Revenue This Year
- PRPH $221.82
- MRKR N/A
- Revenue Next Year
- PRPH N/A
- MRKR $7.16
- P/E Ratio
- PRPH N/A
- MRKR N/A
- Revenue Growth
- PRPH N/A
- MRKR 71.53
- 52 Week Low
- PRPH $0.22
- MRKR $0.95
- 52 Week High
- PRPH $3.00
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- PRPH 35.31
- MRKR 35.51
- Support Level
- PRPH $0.30
- MRKR $1.15
- Resistance Level
- PRPH $0.35
- MRKR $1.61
- Average True Range (ATR)
- PRPH 0.04
- MRKR 0.12
- MACD
- PRPH -0.01
- MRKR -0.04
- Stochastic Oscillator
- PRPH 1.93
- MRKR 16.36
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.